ERCC1 and cancer: While an independently derived ERCC1-XPF interaction inhibitor caused modest enhanced sensitivity to cisplatin in two cancer cell lines and was apparently able, at high concentrations (up to 500 μM), to disrupt the ERCC1-XPF interaction in cell extracts [26].